The combined entity after the merger of Pfizer#39;s off-patent business and Mylan would become the largest generic drug maker globally, and may set the pace for the consolidation of an industry facing pricing pressure amidst competition and channel consolidation in US market.This week in Pharma: Potential Pfizer-Mylan deal could begin consolidation of generic industry
The combined entity after the merger of Pfizer#39;s off-patent business and Mylan would become the largest generic drug maker globally, and may set the pace for the consolidation of an industry facing pricing pressure amidst competition and channel consolidation in US market.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment